Читать книгу Advances in Radiation Therapy - Группа авторов - Страница 29
References
Оглавление1Coley WB: The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases. 1893. Clin Orthop Relat Res 1991;262:3–11.
2Kienle GS: Fever in cancer treatment: Coley’s therapy and epidemiologic observations. Glob Adv Health Med 2012;1:92–100.
3Wiemann B, Starnes CO: Coley’s toxins, tumor necrosis factor and cancer research: a historical perspective. Pharmacol Ther 1994;64:529–564.
4Hanahan D, Weinberg RA: Hallmarks of cancer: the next generation. Cell 2011;144:646–674.
5DeNardo DG, Andreu P, Coussens LM: Interactions between lymphocytes and myeloid cells regulate pro- versus anti-tumor immunity. Cancer Metastasis Rev 2010;29:309–316.
6Grivennikov SI, Greten FR, Karin M: Immunity, inflammation, and cancer. Cell 2010;140:883–899.
7Kim R, Emi M, Tanabe K: Cancer immunoediting from immune surveillance to immune escape. Immunology 2007;121:1–14.
8Teng MW, et al: Immune-mediated dormancy: an equilibrium with cancer. J Leukoc Biol 2008;84:988–993.
9Wolchok JD, et al: Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma. Ann NY Acad Sci 2013;1291:1–13.
10Krummel MF, Allison JP: CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med 1995;182:459–465.
11Tivol EA, et al: Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 1995;3:541–547.
12Hodi FS, et al: Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711–723.
13Hodi FS, et al: Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. Lancet Oncol 2016;17:1558–1568.
14Weber JS, et al: Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 2015;16:375–384.
15Singh P, Black P: Emerging role of checkpoint inhibition in localized bladder cancer. Urol Oncol 2016;34:548–555.
16Longoria TC, Eskander RN: Immune checkpoint inhibition: therapeutic implications in epithelial ovarian cancer. Recent Pat Anticancer Drug Discov 2015;10:133–144.
17Creelan BC: Update on immune checkpoint inhibitors in lung cancer. Cancer Control 2014;21:80–89.
18Rudd CE, Taylor A, Schneider H: CD28 and CTLA-4 coreceptor expression and signal transduction. Immunol Rev 2009;229:12–26.
19Schwartz RH: Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy. Cell 1992;71:1065–1068.
20Peggs KS, et al: Principles and use of anti-CTLA4 antibody in human cancer immunotherapy. Curr Opin Immunol 2006;18:206–213.
21Quezada SA, et al: CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J Clin Invest 2006;116:1935–1945.
22D’Incecco A, et al: PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients. Br J Cancer 2015;112:95–102.
23Velcheti V, et al: Programmed death ligand-1 expression in non-small cell lung cancer. Lab Invest 2014;94:107–116.
24Li X, et al: Emerging immune checkpoints for cancer therapy. Acta Oncol 2015;54:1706–1713.
25Finn OJ: Cancer vaccines: between the idea and the reality. Nat Rev Immunol 2003;3:630–641.
26Joura EA, et al: A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med 2015;372:711–723.
27Janakiram NB, et al: Prophylactic vaccine approach for colon and pancreatic cancers: present and future. Curr Med Chem 2012;19:3664–3678.
28Watson CJ, Gusterson BA: A prophylactic vaccine for breast cancer? Breast Cancer Res 2010;12:310.
29Feyerabend S, et al: Novel multi-peptide vaccination in HLA-A2+ hormone sensitive patients with biochemical relapse of prostate cancer. Prostate 2009;69:917–927.
30Kirner A, Mayer-Mokler A, Reinhardt C: IMA901: a multi-peptide cancer vaccine for treatment of renal cell cancer. Hum Vaccin Immunother 2014;10:3179–3189.
31Higano CS, et al: Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 2009;115:3670–3679.
32Wei XX, Fong L, Small EJ: Prostate cancer immunotherapy with sipuleucel-T: current standards and future directions. Expert Rev Vaccines 2015;14:1529–1541.
33Perez P, et al: Specific targeting of cytotoxic T cells by anti-T3 linked to anti-target cell antibody. Nature 1985;316:354–356.
34Sadelain M, Brentjens R, Riviere I: The basic principles of chimeric antigen receptor design. Cancer Discov 2013;3:388–398.
35Maude SL, et al: CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Blood 2015;125:4017–4023.
36Sim GC, Radvanyi L: The IL-2 cytokine family in cancer immunotherapy. Cytokine Growth Factor Rev 2014;25:377–390.
37Xu HM: Th1 cytokine-based immunotherapy for cancer. Hepatobiliary Pancreat Dis Int 2014;13:482–494.
38Dillman RO, et al: Should high-dose interleukin-2 still be the preferred treatment for patients with metastatic melanoma? Cancer Biother Radiopharm 2012;27:337–343.
39Rosenberg SA: IL-2: the first effective immunotherapy for human cancer. J Immunol 2014;192:5451–5458.
40Letourneau S, et al: IL-2/anti-IL-2 antibody complexes show strong biological activity by avoiding interaction with IL-2 receptor alpha subunit CD25. Proc Natl Acad Sci USA 2010;107:2171–2176.
41Cohen J: IL-12 deaths: explanation and a puzzle. Science 1995;270:908.
42Fallon J, et al: The immunocytokine NHS-IL12 as a potential cancer therapeutic. Oncotarget 2014;5:1869–1884.
43Schliemann C, et al: Complete eradication of human B-cell lymphoma xenografts using rituximab in combination with the immunocytokine L19-IL2. Blood 2009;113:2275–2283.
44Straub JM, et al: Radiation-induced fibrosis: mechanisms and implications for therapy. J Cancer Res Clin Oncol 2015;141:1985–1994.
45Morris JC, et al: Phase I study of GC1008 (fresolimumab): a human anti-transforming growth factor-beta (TGFβ) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma. PLoS One 2014;9:e90353.
46Moran AE, Kovacsovics-Bankowski M, Weinberg AD: The TNFRs OX40, 4-1BB, and CD40 as targets for cancer immunotherapy. Curr Opin Immunol 2013;25:230–237.
47Shi M, et al: Application potential of toll-like receptors in cancer immunotherapy: systematic review. Medicine (Baltimore) 2016;95:e3951.
48Braumuller H, et al: T-helper-1-cell cytokines drive cancer into senescence. Nature 2013;494:361–365.
49Wolchok JD, et al: Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009;15:7412–7420.
50Michot JM, et al: Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer 2016;54:139–148.
51Demaria S, Formenti SC: Radiation as an immunological adjuvant: current evidence on dose and fractionation. Front Oncol 2012;2:153.
52Dudek AM, et al: Inducers of immunogenic cancer cell death. Cytokine Growth Factor Rev 2013;24:319–333.
53Galluzzi L, Kepp O, Kroemer G: Immunogenic cell death in radiation therapy. Oncoimmunology 2013;2:e26536.
54Golden EB, Apetoh L: Radiotherapy and immunogenic cell death. Semin Radiat Oncol 2015;25:11–17.
55Kepp O, et al: Consensus guidelines for the detection of immunogenic cell death. Oncoimmunology 2014;3:e955691.
56Reits EA, et al: Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med 2006;203:1259–1271.
57Lugade AA, et al: Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor. J Immunol 2005;174:7516–7523.
58Matsumura S, et al: Radiation-induced CXCL16 release by breast cancer cells attracts effector T cells. J Immunol 2008;181:3099–3107.
59Aravindan S, et al: Abscopal effect of low-LET gamma-radiation mediated through Rel protein signal transduction in a mouse model of nontargeted radiation response. Cancer Gene Ther 2014;21:54–59.
60Park SS, et al: PD-1 restrains radiotherapy-induced abscopal effect. Cancer Immunol Res 2015;3:610–619.
61Abuodeh Y, Venkat P, Kim S: Systematic review of case reports on the abscopal effect. Curr Probl Cancer 2016;40:25–37.
62Grass GD, Krishna N, Kim S: The immune mechanisms of abscopal effect in radiation therapy. Curr Probl Cancer 2016;40:10–24.
63Postow MA, et al: Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med 2012;366:925–931.
64Mendes F, et al: The role of immune system exhaustion on cancer cell escape and anti-tumor immune induction after irradiation. Biochim Biophys Acta 2016;1865:168–175.
65Wunderlich R, et al: Low and moderate doses of ionizing radiation up to 2 Gy modulate transmigration and chemotaxis of activated macrophages, provoke an anti-inflammatory cytokine milieu, but do not impact upon viability and phagocytic function. Clin Exp Immunol 2015;179:50–61.
66Twyman-Saint VC, et al: Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature 2015;520:373–377.
67Belcaid Z, et al: Focal radiation therapy combined with 4-1BB activation and CTLA-4 blockade yields long-term survival and a protective antigen-specific memory response in a murine glioma model. PLoS One 2014;9:e101764.
68Demaria S, et al: Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clin Cancer Res 2005;11:728–734.
69Dewan MZ, et al: Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin Cancer Res 2009;15:5379–5388.
70Sharabi AB, et al: Stereotactic radiation therapy augments antigen-specific PD-1-mediated antitumor immune responses via cross-presentation of tumor antigen. Cancer Immunol Res 2015;3:345–355.
71Zeng J, et al: Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas. Int J Radiat Oncol Biol Phys 2013;86:343–349.
72Grimaldi AM, et al: Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy. Oncoimmunology 2014;3:e28780.
73Kwon ED, et al: Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol 2014;15:700–712.
74Trump D: Commentary on: “Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial.” Urol Oncol 2016;34:249–250.
75Vanpouille-Box C, et al: In situ vaccination by radiotherapy to improve responses to anti-CTLA-4 treatment. Vaccine 2015;33:7415–7422.
76Garnett-Benson C, Hodge JW, Gameiro SR: Combination regimens of radiation therapy and therapeutic cancer vaccines: mechanisms and opportunities. Semin Radiat Oncol 2015;25:46–53.
77Mondini M, et al: Synergy of radiotherapy and a cancer vaccine for the treatment of HPV-associated head and neck cancer. Mol Cancer Ther 2015;14:1336–1345.
78Fotin-Mleczek M, et al: mRNA-based vaccines synergize with radiation therapy to eradicate established tumors. Radiat Oncol 2014;9:180.
79Sebastian M, et al: Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine (RNActive®) combined with local radiation as consolidation and maintenance treatment for patients with stage IV non-small cell lung cancer. BMC Cancer 2014;14:748.
80Lechleider RJ, et al: Safety and immunologic response of a viral vaccine to prostate-specific antigen in combination with radiation therapy when metronomic-dose interleukin 2 is used as an adjuvant. Clin Cancer Res 2008;14:5284–5291.
81Kamrava M, et al: Long-term follow-up of prostate cancer patients treated with vaccine and definitive radiation therapy. Prostate Cancer Prostatic Dis 2012;15:289–295.
82Haji-Fatahaliha M, et al: CAR-modified T-cell therapy for cancer: an updated review. Artif Cells Nanomed Biotechnol 2016;44:1339–1349.
83Lameris R, et al: Bispecific antibody platforms for cancer immunotherapy. Crit Rev Oncol Hematol 2014;92:153–165.
84Weidle UH, Kontermann RE, Brinkmann U: Tumor-antigen-binding bispecific antibodies for cancer treatment. Semin Oncol 2014;41:653–660.
85Cartellieri M, et al: TCR/CD3 activation and co-stimulation combined in one T cell retargeting system improve anti-tumor immunity. Oncoimmunology 2013;2:e26770.
86Zegers CM, et al: Radiotherapy combined with the immunocytokine L19-IL2 provides long-lasting antitumor effects. Clin Cancer Res 2015;21:1151–1160.
87Rekers NH, et al: Long-lasting antitumor effects provided by radiotherapy combined with the immunocytokine L19-IL2. Oncoimmunology 2015;4:e1021541.
88Rekers NH, et al: Combination of radiotherapy with the immunocytokine L19-IL2: additive effect in a NK cell dependent tumour model. Radiother Oncol 2015;116:438–442.
89van den Heuvel MM, et al: NHS-IL2 combined with radiotherapy: preclinical rationale and phase Ib trial results in metastatic non-small cell lung cancer following first-line chemotherapy. J Transl Med 2015;13:32.
90Schilbach K, et al: Cancer-targeted IL-12 controls human rhabdomyosarcoma by senescence induction and myogenic differentiation. Oncoimmunology 2015;4:e1014760.
91Paoloni M, et al: Defining the pharmacodynamic profile and therapeutic index of NHS-IL12 immunocytokine in dogs with malignant melanoma. PLoS One 2015;10:e0129954.
92Eckert F, et al: Enhanced binding of necrosis-targeting immunocytokine NHS-IL12 after local tumour irradiation in murine xenograft models. Cancer Immunol Immunother 2016;65:1003–1013.
93Kang J, Demaria S, Formenti S: Current clinical trials testing the combination of immunotherapy with radiotherapy. J Immunother Cancer 2016;4:51.
94Kulzer L, et al: Norm- and hypo-fractionated radiotherapy is capable of activating human dendritic cells. J Immunotoxicol 2014;11:328–336.
95Gandhi SJ, et al: Awakening the immune system with radiation: optimal dose and fractionation. Cancer Lett 2015;368:185–190.
96Golden EB, et al: An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer. Cancer Immunol Res 2013;1:365–372.
97Eckert F, Jelas I, Oehme M, Huber SM, Sonntag K, Welker C, Gillies SD, Strittmatter W, Zips D, Handgretinger R, Schilbach K: Tumor-targeted IL-12 combined with local irradiation leads to systemic tumor control via abscopal effects in vivo. Oncoimmunology 2017;6:e1323161.
Franziska Eckert, MD
Department of Radiation Oncology, Eberhard Karls University of Tübingen
Hoppe-Seyler-Strasse 3
DE–2076 Tübingen (Germany)
